Trade Report: The Quantitative Systematic Strategies LLC Acquires Shares of 9,723 Alexion Pharmaceuticals Inc. (ALXN)

The Quantitative Systematic Strategies LLC Acquires Shares of 9,723 Alexion Pharmaceuticals Inc. (ALXN)

Quantitative Systematic Strategies LLC acquired a new stake in Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) during the second quarter, Holdings Channel reports. The firm acquired 9,723 shares of the biopharmaceutical company’s stock, valued at approximately $1,110,000. Alexion Pharmaceuticals makes up about 0.5% of Quantitative Systematic Strategies LLC’s holdings, making the stock its 24th largest position.

A number of other large investors also recently added to or reduced their stakes in ALXN. Glenmede Trust Co. NA raised its stake in Alexion Pharmaceuticals by 38.1% in the first quarter. Glenmede Trust Co. NA now owns 3,077 shares of the biopharmaceutical company’s stock valued at $427,000 after buying an additional 849 shares in the last quarter. Virginia Retirement System bought a new stake in Alexion Pharmaceuticals during the first quarter valued at approximately $509,000. Nikko Asset Management Americas Inc. bought a new stake in Alexion Pharmaceuticals during the first quarter valued at approximately $297,000. NN Investment Partners Holdings N.V. bought a new stake in Alexion Pharmaceuticals during the first quarter valued at approximately $9,685,000. Finally, TimesSquare Capital Management LLC raised its stake in Alexion Pharmaceuticals by 430.2% in the first quarter. TimesSquare Capital Management LLC now owns 39,555 shares of the biopharmaceutical company’s stock valued at $5,507,000 after buying an additional 32,095 shares in the last quarter. Institutional investors and hedge funds own 96.34% of the company’s stock.

Shares of Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) traded up 1.76% during trading on Friday, reaching $125.05. The company had a trading volume of 1,009,863 shares. Alexion Pharmaceuticals Inc. has a 52 week low of $110.56 and a 52 week high of $193.45. The firm has a 50-day moving average of $127.95 and a 200 day moving average of $134.91. The firm has a market capitalization of $28.04 billion, a price-to-earnings ratio of 314.20 and a beta of 1.33.

Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.13 EPS for the quarter, missing analysts’ consensus estimates of $1.17 by $0.04. The business earned $753 million during the quarter, compared to analysts’ expectations of $743.18 million. Alexion Pharmaceuticals had a net margin of 3.19% and a return on equity of 10.02%. The company’s revenue for the quarter was up 18.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.44 EPS. On average, equities research analysts forecast that Alexion Pharmaceuticals Inc. will post $4.67 earnings per share for the current year.

ALXN has been the topic of several recent research reports. Robert W. Baird restated a “neutral” rating and issued a $145.00 price objective on shares of Alexion Pharmaceuticals in a research report on Monday, June 13th. Leerink Swann restated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Friday, June 17th. Citigroup Inc. upgraded Alexion Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $154.00 price objective on the stock in a research report on Monday, June 27th. Piper Jaffray Cos. reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research report on Sunday, June 26th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research report on Wednesday, June 29th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $178.32.

In other Alexion Pharmaceuticals news, CFO Vikas Sinha sold 277 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $137.14, for a total transaction of $37,987.78. Following the transaction, the chief financial officer now owns 178,463 shares of the company’s stock, valued at approximately $24,474,415.82. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO David Hallal sold 332 shares of the stock in a transaction that occurred on Monday, August 8th. The stock was sold at an average price of $137.14, for a total value of $45,530.48. Following the transaction, the chief executive officer now directly owns 189,266 shares in the company, valued at approximately $25,955,939.24. The disclosure for this sale can be found here. 4.41% of the stock is owned by corporate insiders.

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of life-transforming therapeutic products. The Company operates through innovation, development and commercialization of life-transforming therapeutic products segment. The Company’s marketed products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).

Related posts

Leave a Comment